Nature Reviews Drug Discovery

From gene hunter to drug hunter

Asher Mullard Sep 01, 2025 pp. 658-659 10.1038/d41573-025-00139-2

Leading orexin receptor agonist clears phase III for narcolepsy

Asher Mullard Sep 01, 2025 pp. 655-655 10.1038/d41573-025-00137-4

FDA grants first US approval for decades-old eye drug

Asher Mullard Sep 01, 2025 pp. 655-655 10.1038/d41573-025-00138-3

Small-molecule PI3Kα binder with selective anticancer activity

Katie Kingwell Sep 01, 2025 pp. 664-664 10.1038/d41573-025-00136-5

In vivo engineering broadens CAR-T cell therapy use

M. Teresa Villanueva Sep 01, 2025 pp. 664-664 10.1038/d41573-025-00134-7

Broader horizons for cereblon glue degraders

Alex Eccleston Sep 01, 2025 pp. 662-662 10.1038/d41573-025-00133-8

Trends in the development of cellular and gene therapy in China

Yantong Liu, Chenghao Ge, Xiaoyuan Chen et al. Sep 01, 2025 pp. 656-657 10.1038/d41573-025-00126-7

Oncolytic virus drought continues, as Replimune fails to secure FDA cancer approval

Asher Mullard Sep 01, 2025 pp. 654-654 10.1038/d41573-025-00132-9

In vivo CAR T cells gain traction, with AbbVie’s US$2.1 billion acquisition of Capstan Therapeutics

Asher Mullard Sep 01, 2025 pp. 653-653 10.1038/d41573-025-00131-w

Mimicking the health benefits of exercise

Sarah Crunkhorn Sep 01, 2025 pp. 665-665 10.1038/d41573-025-00127-6

De novo design of macrocycles

Sarah Crunkhorn Sep 01, 2025 pp. 665-665 10.1038/d41573-025-00129-4

Neoantigen-targeting vaccine treats melanoma

Sarah Crunkhorn Sep 01, 2025 pp. 665-665 10.1038/d41573-025-00128-5

PDE5 inhibitor restores dendritic cell migration

Sarah Crunkhorn Sep 01, 2025 pp. 665-665 10.1038/d41573-025-00130-x

Biased adrenergic receptor agonist tackles metabolic disease

Sarah Crunkhorn Sep 01, 2025 pp. 663-663 10.1038/d41573-025-00125-8

Unmet needs in vaccine development

Jennifer Heller, Tania Holt, Leah Kaplow et al. Sep 01, 2025 pp. 660-661 10.1038/d41573-025-00100-3

Generative AI: a generation-defining shift for biopharma regulatory affairs

Jon Williams, Donna Boyce, Graziella Collu et al. Sep 01, 2025 pp. 651-652 10.1038/d41573-025-00089-9

The gut microbiome as a target in cancer immunotherapy: opportunities and challenges for drug development

Arielle Elkrief, Reilly Pidgeon, Saman Maleki Vareki et al. Sep 01, 2025 pp. 685-704 10.1038/s41573-025-01211-7

Targeting neutrophils for cancer therapy

Jeff W. Kwak, A. McGarry Houghton Sep 01, 2025 pp. 666-684 10.1038/s41573-025-01210-8

Application of new approach methodologies for nonclinical safety assessment of drug candidates

Mario Beilmann, Karissa Adkins, Harrie C. M. Boonen et al. Sep 01, 2025 pp. 705-725 10.1038/s41573-025-01182-9